ECSP056206A - Inhibidores de quinasa p38 basados en heterociclos de 5 miembros - Google Patents

Inhibidores de quinasa p38 basados en heterociclos de 5 miembros

Info

Publication number: ECSP056206A
Authority: EC; Ecuador
Prior art keywords: kinase; heterocicles; quinasa; inhibitors; inhibitors based
Prior art date: 2003-06-26

Application number

EC2005006206A

Other languages

English (en)

Spanish (es)

Inventor

Olga M Fryszman

Hengyuan Lang

Jiong Lan

Edcon Chang

Yunfeng Fang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2005-12-08

Publication date

2006-04-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34108816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-08 Application filed by Novartis Ag filed Critical Novartis Ag

2006-04-19 Publication of ECSP056206A publication Critical patent/ECSP056206A/es

Links

239000012826 P38 inhibitor Substances 0.000 title 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
208000027866 inflammatory disease Diseases 0.000 abstract 2
102000001253 Protein Kinase Human genes 0.000 abstract 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)

EC2005006206A 2003-06-26 2005-12-08 Inhibidores de quinasa p38 basados en heterociclos de 5 miembros ECSP056206A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US48342803P	2003-06-26	2003-06-26
US49905403P	2003-08-29	2003-08-29
US56048104P	2004-04-07	2004-04-07

Publications (1)

Publication Number	Publication Date
ECSP056206A true ECSP056206A (es)	2006-04-19

Family

ID=34108816

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EC2005006206A ECSP056206A (es)	2003-06-26	2005-12-08	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros
ECSP12006206 ECSP12006206A (es)	2003-06-26	2012-02-07	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ECSP12006206 ECSP12006206A (es)	2003-06-26	2012-02-07	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.

Country Status (26)

Country	Link
US (4)	US7863314B2 (is)
EP (2)	EP1641764B1 (is)
JP (1)	JP4838121B2 (is)
KR (1)	KR101120857B1 (is)
CN (1)	CN1832928B (is)
AT (1)	ATE517872T1 (is)
AU (1)	AU2004259662B2 (is)
BR (1)	BRPI0411825B8 (is)
CA (1)	CA2526455C (is)
CY (2)	CY1111985T1 (is)
DK (2)	DK2298743T3 (is)
EC (2)	ECSP056206A (is)
ES (1)	ES2393950T3 (is)
HR (2)	HRP20110757T1 (is)
IL (1)	IL172182A (is)
IS (2)	IS2916B (is)
MA (1)	MA27888A1 (is)
MX (1)	MXPA05013824A (is)
MY (1)	MY158162A (is)
NO (1)	NO334947B1 (is)
NZ (1)	NZ544230A (is)
PL (2)	PL2298743T3 (is)
PT (2)	PT2298743E (is)
SI (2)	SI1641764T1 (is)
TW (2)	TWI449696B (is)
WO (1)	WO2005009973A1 (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7485657B2 (en)	2004-05-12	2009-02-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
CA2606226A1 (en) *	2005-04-27	2006-11-02	University Of Florida Research Foundation, Inc.	Materials and methods for enhanced degradation of mutant proteins associated with human disease
DE102005031580A1 (de) *	2005-07-06	2007-01-11	Aicuris Gmbh & Co. Kg	Substituierte Sulfolanylpyrazole und ihre Verwendung
GB0603684D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
HUE026011T2 (en)	2006-03-22	2016-05-30	Hoffmann La Roche	Pyrazoles as 11-beta-HSD-1
JP2009532495A (ja) *	2006-04-03	2009-09-10	ストワーズインスティテュートフォーメディカルリサーチ	多発性嚢胞腎の治療用の組成物及び治療方法
WO2008052974A1 (en) *	2006-10-30	2008-05-08	Novartis Ag	3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
GB0621978D0 (en) *	2006-11-03	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2008276451A1 (en) *	2007-07-17	2009-01-22	Zalicus Inc.	Treatments of B-cell proliferative disorders
TW200914048A (en) *	2007-07-17	2009-04-01	Combinatorx Inc	Combinations for the treatment of B-cell proliferative disorders
HRP20151052T1 (xx)	2007-07-19	2015-11-06	H. Lundbeck A/S	Peteroäślani heterocikliäśki amidi i srodne tvari
US8119800B2 (en) *	2007-12-21	2012-02-21	Korea Research Institute Of Chemical Technology	Processes for preparing HIV reverse transcriptase inhibitors
DE102008015033A1 (de) *	2008-03-17	2009-09-24	Aicuris Gmbh & Co. Kg	Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US20090281150A1 (en) *	2008-04-09	2009-11-12	Nicola Frances Bateman	Compound 249
US20100009934A1 (en) *	2008-06-09	2010-01-14	Combinatorx, Incorporated	Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010014913A1 (en)	2008-08-01	2010-02-04	Ventirx Pharmaceuticals, Inc.	Toll-like receptor agonist formulations and their use
ES2545275T3 (es)	2008-11-06	2015-09-09	Ventirx Pharmaceuticals, Inc.	Métodos de síntesis de derivados de benzazepinas
HRP20151258T1 (hr)	2009-08-07	2016-02-26	Chugai Seiyaku Kabushiki Kaisha	Derivat aminopirazola
CN105669553A (zh)	2009-08-18	2016-06-15	文蒂雷克斯药品公司	作为toll样受体调节剂的取代的苯并氮杂*
RU2016108987A (ru)	2009-08-18	2018-11-26	Вентиркс Фармасьютикалз, Инк.	Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
WO2011038261A1 (en) *	2009-09-24	2011-03-31	Selexagen Therapeutics, Inc.	Heterocyclic kinase inhibitors
WO2011100769A2 (en) *	2010-02-15	2011-08-18	Synovo Gmbh	Kinase modulators for the treatment of cancer
PE20131343A1 (es) *	2010-09-21	2013-11-18	Eisai Randd Man Co Ltd	Derivados de acido benzoico
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
EP2460519A1 (en) *	2010-12-03	2012-06-06	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in bone cancer pain
JP5620417B2 (ja) *	2011-02-07	2014-11-05	中外製薬株式会社	アミノピラゾール誘導体を含む医薬
WO2013139809A1 (en) *	2012-03-20	2013-09-26	Novartis Ag	Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
WO2015084936A1 (en) *	2013-12-04	2015-06-11	The Scripps Research Institute	Novel compounds as jnk kinase inhibitors
RU2653504C2 (ru)	2013-12-13	2018-05-10	Ф. Хоффманн-Ля Рош Аг	Ингибиторы тирозинкиназы брутона
US9802920B2 (en)	2013-12-13	2017-10-31	Hoffman-La Roche Inc.	Inhibitors of bruton's tyrosine kinase
JP6514645B2 (ja)	2013-12-27	2019-05-15	中外製薬株式会社	Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
JP6762300B2 (ja)	2015-06-17	2020-09-30	中外製薬株式会社	アミノピラゾール誘導体
WO2017028816A1 (zh) *	2015-08-20	2017-02-23	浙江海正药业股份有限公司	吲哚类衍生物及其制备方法和其在医药上的用途
KR102762199B1 (ko) *	2016-03-08	2025-02-07	메레오 바이오파마 1 리미티드	만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
BR112018067784A2 (pt)	2016-03-08	2019-01-15	Mereo Biopharma 1 Ltd	regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias
GB201612238D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) *	2016-09-29	2018-04-05	南京明德新药研发股份有限公司	p38αMAPK激酶抑制剂及其制备方法和应用
EP3554257B1 (en)	2016-12-15	2023-07-12	Société des Produits Nestlé S.A.	Compositions and methods that modulate white blood cells or neutrophils in a companion animal
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt)	2017-10-05	2020-10-06	Fulcrum Therapeutics, Inc.	uso de inibidores p38 para reduzir a expressão de dux4
AU2018381874B2 (en)	2017-12-11	2024-08-15	Mereo Biopharma 1 Limited	Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
JP7280627B2 (ja)	2017-12-11	2023-05-24	メレオバイオファーマ１リミテッド	慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
EP3773579A4 (en)	2018-03-26	2022-03-09	Clear Creek Bio, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP3563848A1 (en) *	2018-04-30	2019-11-06	S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati	Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815699D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815696D0 (en)	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815695D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
CN110950848B (zh) *	2018-09-27	2024-03-26	徐诺药业	新型氨基吡唑类衍生物的合成与应用
EP3880666B1 (en)	2018-11-13	2023-06-28	Novartis AG	Compounds and compositions for treating conditions associated with nlrp activity
CN113015730A (zh) *	2018-11-13	2021-06-22	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
WO2021189018A1 (en)	2020-03-20	2021-09-23	Clear Creek Bio, Inc.	Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN112778333B (zh) *	2021-01-23	2022-07-05	中国科学院新疆理化技术研究所	一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途
WO2026011033A1 (en) *	2024-07-03	2026-01-08	Empire Discovery Institute	P38gamma inhibitors and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1152421B (de)	1961-03-21	1963-08-08	Bayer Ag	Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen
JPS5111499Y2 (is)	1971-04-22	1976-03-27
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
JPS5527916B2 (is)	1973-02-05	1980-07-24
JPS51112341A (en)	1975-02-24	1976-10-04	Konishiroku Photo Ind Co Ltd	Magenta dye image formation
US4200750A (en)	1977-01-07	1980-04-29	Westwood Pharmaceuticals Inc.	4-Substituted imidazo [1,2-a]quinoxalines
CZ284157B6 (cs)	1992-12-17	1998-08-12	Pfizer Inc.	Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US6005109A (en)	1997-10-30	1999-12-21	Pflizer Inc.	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6103900A (en)	1992-12-17	2000-08-15	Pfizer Inc	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5514643A (en)	1993-08-16	1996-05-07	Lucky Ltd.	2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
US5646152A (en)	1994-06-15	1997-07-08	Pfizer Inc.	Methods of administering CRF antagonists
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE19518054A1 (de)	1995-03-08	1996-09-12	Hoechst Schering Agrevo Gmbh	N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
PL187516B1 (pl)	1996-01-11	2004-07-30	Smithkline Beecham Corp	Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US5945418A (en)	1996-12-18	1999-08-31	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
AU730224B2 (en)	1996-12-23	2001-03-01	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
IL132736A0 (en)	1997-05-22	2001-03-19	Searle & Co	3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
PL342447A1 (en)	1997-10-27	2001-06-04	Agouron Pharma	Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
US6376527B1 (en)	1998-05-05	2002-04-23	Syntex (U.S.A.) Llc	Pyrazole derivatives-p38 map kinase inhibitors
US6316466B1 (en)	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
US20020156114A1 (en)	1998-05-05	2002-10-24	Goldstein David Michael	Pyrazole derivatives - p38 MAP kinase inhibitors
HRP20000724A2 (en) *	1998-05-05	2001-06-30	Hoffmann La Roche	Pyrazole derivatives as p-38 map kinase inhibitors
US6130235A (en)	1998-05-22	2000-10-10	Scios Inc.	Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
MXPA01002173A (es)	1998-08-28	2003-07-14	Scios Inc	Inhibidores de p38-alfa cinasa.
WO2000025780A1 (en)	1998-10-29	2000-05-11	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
EP1169038B9 (en)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
ES2237470T3 (es)	1999-11-10	2005-08-01	Ortho-Mcneil Pharmaceutical, Inc.	2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
AU2001230026A1 (en)	2000-02-04	2001-08-14	Novo-Nordisk A/S	2,4-diaminothiazole derivatives
JP2004509863A (ja)	2000-09-21	2004-04-02	ブリストル−マイヤーズ　スクイブ　カンパニー	コルチコトロピン放出因子のインヒビターとしての置換アゾール誘導体
GEP20063915B (en)	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
AU2002219678A1 (en)	2001-01-17	2002-07-30	Boyean Kim	Sun visor having office work apparatus
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
WO2002092087A1 (en)	2001-05-11	2002-11-21	Vertex Pharmaceuticals Incorporated	2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
HN2002000156A (es)	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0124928D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
AU2004309420B2 (en) *	2003-12-23	2008-10-30	Novartis Ag	Bicyclic heterocyclic p-38 kinase inhibitors
JP2007084437A (ja)	2003-12-26	2007-04-05	Dai Ichi Seiyaku Co Ltd	アミノアルキルピラゾール誘導体

2004
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 EP EP04777075A patent/EP1641764B1/en not_active Expired - Lifetime
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 EP EP10164367A patent/EP2298743B1/en not_active Expired - Lifetime
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/en not_active Ceased
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es not_active Expired - Lifetime
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja not_active Expired - Lifetime
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh not_active Expired - Lifetime
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko not_active Expired - Lifetime
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en not_active IP Right Cessation
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 CA CA2526455A patent/CA2526455C/en not_active Expired - Lifetime
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en not_active Expired
- 2004-06-25 US US10/877,534 patent/US7863314B2/en not_active Expired - Lifetime
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en not_active Expired - Lifetime
2011
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en not_active Expired - Fee Related
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en not_active Expired - Fee Related
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown

Also Published As

Publication number	Publication date
BRPI0411825B1 (pt)	2018-11-06
DK2298743T3 (da)	2012-11-26
JP4838121B2 (ja)	2011-12-14
CA2526455A1 (en)	2005-02-03
US20050049288A1 (en)	2005-03-03
IS8255A (is)	2006-01-23
NO334947B1 (no)	2014-08-04
DK1641764T3 (da)	2011-11-21
TWI452035B (zh)	2014-09-11
EP1641764B1 (en)	2011-07-27
PT1641764E (pt)	2011-10-27
US8580838B2 (en)	2013-11-12
MXPA05013824A (es)	2006-02-28
PL2298743T3 (pl)	2013-02-28
ATE517872T1 (de)	2011-08-15
BRPI0411825B8 (pt)	2021-05-25
AU2004259662A1 (en)	2005-02-03
BRPI0411825A (pt)	2006-08-08
CN1832928A (zh)	2006-09-13
HRP20120900T1 (hr)	2012-11-30
SI2298743T1 (sl)	2012-12-31
ES2393950T3 (es)	2013-01-02
MY158162A (en)	2016-09-15
CY1113313T1 (el)	2016-04-13
EP2298743A1 (en)	2011-03-23
US20130172352A1 (en)	2013-07-04
AU2004259662B2 (en)	2008-08-07
HK1149764A1 (en)	2011-10-14
TW201125854A (en)	2011-08-01
WO2005009973A1 (en)	2005-02-03
IS2984B (is)	2017-09-15
IS2916B (is)	2014-12-15
CA2526455C (en)	2012-10-09
KR101120857B1 (ko)	2012-04-12
CY1111985T1 (el)	2015-11-04
PL1641764T3 (pl)	2011-12-30
CN1832928B (zh)	2012-07-04
SI1641764T1 (sl)	2011-11-30
IL172182A (en)	2014-07-31
EP2298743B1 (en)	2012-08-22
TW200510328A (en)	2005-03-16
NZ544230A (en)	2009-07-31
PT2298743E (pt)	2012-12-04
US20120264801A1 (en)	2012-10-18
EP1641764A1 (en)	2006-04-05
TWI449696B (zh)	2014-08-21
KR20060024813A (ko)	2006-03-17
ECSP12006206A (es)	2012-03-30
NO20060424L (no)	2006-03-15
US20110071152A1 (en)	2011-03-24
IS9037A (is)	2014-01-28
US7863314B2 (en)	2011-01-04
MA27888A1 (fr)	2006-05-02
US8410160B2 (en)	2013-04-02
US8242117B2 (en)	2012-08-14
HRP20110757T1 (hr)	2011-11-30
HK1088895A1 (en)	2006-11-17
JP2007521278A (ja)	2007-08-02

Publication	Publication Date	Title
ECSP12006206A (es)	2012-03-30	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
BRPI0410905A (pt)	2006-06-27	inibidores de p-38
ATE457313T1 (de)	2010-02-15	Bicyclische heterocyclische p-38-kinase- inhibitoren
WO2004098589A8 (en)	2005-12-08	4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
CY1106816T1 (el)	2012-01-25	1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
NO20050807L (no)	2005-02-15	Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
WO2004080423A3 (en)	2004-11-04	7-amino- isoindolyl compounds amd their pharmaceutical uses
ATE402176T1 (de)	2008-08-15	Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
ATE551335T1 (de)	2012-04-15	Indolylmaleimid-derivate
NO20024662L (no)	2002-09-27	Prodroger av imidazopyridinderivater
TNSN05307A1 (en)	2007-07-10	5-membered heterocycle-based p38 kinase inhibitors